Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 6/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.45 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.45 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857645 | 0.81 | GRIK1 (0.60) | GRIK1GRIK2GRIK3CYP1A2ALDH1A1 | |
| SCHEMBL1857647 | 0.81 | GRIK1 (0.60) | GRIK1GRIK2GRIK3CYP1A2ALDH1A1 | |
| SCHEMBL1748144 | 0.75 | CYP1A2 (0.50) | GRIK1ANPEPCYP1A2 | |
| SCHEMBL1857365 | 0.74 | CYP1A2 (0.61) | GRIK1ANPEPCYP1A2 | |
| SCHEMBL9748537 | 0.73 | CYP2C19 (0.50) | GRIK1GRIK2ANPEPCYP1A2CYP2C19 | |
| SCHEMBL7439191 | 0.72 | GRIK1 (0.64) | GRIK1ANPEPCYP1A2 | |
| SCHEMBL7439419 | 0.72 | GRIK1 (0.64) | GRIK1ANPEPCYP1A2 | |
| Water SCHEMBL4010621 | 0.72 | CYP1A2 (0.59) | GRIK1ANPEPCYP1A2 | |
| SCHEMBL7439193 | 0.72 | GRIK1 (0.64) | GRIK1ANPEPCYP1A2 | |
| SCHEMBL3466551 | 0.71 | FFAR1 (0.51) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | GRIK1 3852/4885GRIK2 4227/4885GRIK3 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.